Blueprint Medicines Corp (BPMC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 138,157 | 96,116 | 71,957 | 56,566 | 57,570 |
| Cost of Goods | 7,593 | 3,191 | 215 | 4,553 | 3,557 |
| Gross Profit | 130,564 | 92,925 | 71,742 | 52,013 | 54,013 |
| Operating Expenses | 174,202 | 171,939 | 177,066 | 181,546 | 182,551 |
| Operating Income | -43,045 | -78,823 | -105,109 | -128,980 | -127,981 |
| Interest Expense | 6,864 | 5,895 | 0 | 3,808 | 3,996 |
| Other Income | 17 | 174,034 | -5,748 | -728 | -626 |
| Pre-tax Income | -49,892 | 89,316 | -110,857 | -133,516 | -132,603 |
| Income Tax | 102 | 180 | 61 | 197 | 190 |
| Net Income Continuous | -49,994 | 89,136 | -110,918 | -133,713 | -132,793 |
| Net Income | $-49,994 | $89,136 | $-110,918 | $-133,713 | $-132,793 |
| EPS Basic Total Ops | -0.80 | 1.45 | -1.83 | -2.20 | -2.19 |
| EPS Basic Continuous Ops | -0.80 | 1.45 | -1.82 | -2.20 | -2.19 |
| EPS Diluted Total Ops | -0.80 | 1.40 | -1.83 | -2.20 | -2.19 |
| EPS Diluted Continuous Ops | -0.80 | 1.40 | -1.82 | -2.20 | -2.19 |
| EPS Diluted Before Non-Recurring Items | -0.80 | -1.32 | -1.82 | -2.20 | -2.19 |
| EBITDA(a) | $-45,073 | $-79,206 | $-109,517 | $-131,545 | $-128,113 |